Combined detection of P53, Ki67, P504S, and IMP3: Diagnostic implications for gastric cancer and precursor lesions

Table 1 Expression of P504S and IMP3 in gastric mucosal biopsies at different stages, n (%)

	AH	LGD	HGD	AC	P value
P504S					< 0.001
-	48 (100)	14 (46.7)	29 (64.4)	40 (64.5)
+	0	16 (53.3)	16 (35.6)	22 (35.5)
IMP3					< 0.001
-	47 (97.9)	29 (96.7)	30 (66.7)	36 (58.1)
+	1 (2.1)	1 (3.3)	15 (33.3)	26 (41.9)

-: Absent; +: Present; AH: Atypical hyperplasia; LGD: Low-grade dysplasia; HGD: High-grade dysplasia; AC: Adenocarcinoma.

Table 2 Sensitivity and specificity of P504S, Ki67, and their combination for diagnosing low-grade dysplasia

	Group		Sensitivity	Specificity
	Others1	LGD
P504S			53.33%	75.48%
-	117	14
+	38	16
Ki67			76.67%	95.48%
Others (-)	148	7
Polarity (+)	7	23
Combination of P504S and Ki672			90.00%	73.55%
-	114	3
+	41	27

¹Others include atypical hyperplasia, high-grade dysplasia, and adenocarcinoma.

²P504S and Ki67 are used in parallel for the combined diagnosis of low-grade dysplasia.

LGD: Low-grade dysplasia.

Table 3 Sensitivity and specificity of P53, IMP3, and their combination for diagnosing high-grade dysplasia/adenocarcinoma

	Group		Sensitivity (%)	Specificity (%)
	AH/LGD	HGD/AC
P53			71.03	97.44
Wild-type (-)	76	31
Mutation-type (+)	2	76
IMP3			38.32	97.44
-	76	66
+	2	41
Combination of P53 and IMP31			76.64	96.15
-	75	25
+	3	82

¹P53 and IMP3 are used in parallel for the combined diagnosis of high-grade dysplasia/adenocarcinoma.

AH: Atypical hyperplasia; LGD: Low-grade dysplasia; HGD: High-grade dysplasia; AC: Adenocarcinoma.